The global prediabetes treatment market accounted for USD 202.7 million in 2023 and is expected to reach at USD 436.4 million by 2034 with a CAGR of 7.22% during the forecast period 2024-2034. Rising prevalence of conditions causing insulin resistance & disrupted glucose metabolism, increasing prevalence of various correlated risk factors, including sedentary lifestyles, obesity, & unhealthy dietary habits, surge in the adoption of continuous glucose monitoring (CGM) devices, increased use of technology for the diagnosis of prediabetes, and growing introduction of innovative drug products for treating prediabetes are some of the key factors boosting the market growth.
Growing introduction of innovative drug products for treating prediabetes is predicted to boost the market growth during the forecast period. Prediabetes represents a transitional phase in glucose regulation, positioned between typical glucose tolerance and diagnosed diabetes. Individuals with prediabetes have elevated blood glucose levels beyond the normal range but do not meet the criteria for a diabetes diagnosis. Expressions such as impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are employed to describe this prediabetic state. Consequently, companies in the market are introducing new drug products specifically designed for treating prediabetes. For instance, in January 2024, Novo Nordisk has introduced Wegovy, a GLP-1 analogue, in the United Kingdom. This medication is available for prescription for individuals with prediabetes and for those seeking weight loss.
By age group, adults (18-49) was the highest revenue-grossing segment in the global prediabetes treatment market in 2023 owing to the growing prevalence of prediabetes and increased adoption of unhealthy lifestyles. Additionally, elderly (50+) is predicted to grow at the fastest CAGR during the forecast period owing to the rising geriatric population, expanding range of medication choices for prediabetes treatment, and increasing research & development efforts. For instance, in November 2023, VALBIOTIS SA reported the positive outcome of the mode-of-action clinical study for its product TOTUM•63 in the treatment of prediabetes.
By drug class, diguanides was the highest revenue-grossing segment in the global prediabetes treatment market in 2023 as their extensive use in managing prediabetes & type 2 diabetes, and increasing trend in the adoption of metformin for prediabetes treatment. Additionally, SGLT2 inhibitors is predicted to grow at the fastest CAGR during the forecast period owing to the growing use in the treatment for prediabetes, and increase in the number of clinical trial procedures. For instance, in April 2023, Aphaia Pharma has commenced the Phase 2 Trial for its potential drug, APH-012, intended for treating prediabetes.
By end-user, diagnostic center was the highest revenue-grossing segment in the global prediabetes treatment market in 2023 owing to the growing prevalence of prediabetes in the population, rise in the number of diagnostic tests, and increased efforts by market participants. For instance, in October 2023, The Ministry of Health and Prevention (MoHAP) has introduced a groundbreaking National Prediabetes and Diabetes Screening initiative. Utilizing screening centers throughout the UAE, the campaign aligns with the goal of achieving the National Indicator to decrease diabetes prevalence in the country. Additionally, hospitals is predicted to grow at the fastest CAGR during the forecast period owing to the upswing in the number of individuals affected by diabetes and growing need for innovative drug products designed for the treatment of prediabetes.
North America region is anticipated for the highest revenue share during the forecast period owing to the heightened awareness regarding the significance of early identification & intervention for prediabetes, rising prevalence of prediabetes, continuous progress in diagnostic technologies & therapeutic alternatives, and increase in research & development efforts. For instance, in July 2022, A patented extract of flavonoids derived from lemon, marketed under the name Eriomin by Ingredients By Nature (IMN), has been shown to be advantageous in the management of prediabetes, as reported in a study published in the Journal of Medical Food. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the widespread adoption of sedentary lifestyles, rising prevalence of prediabetes, surge in genetic predisposition, growing aging population, escalating prevalence obesity, and increasing number of approvals by regulatory bodies. For instance, in May 2022, The U.S. Food and Drug Administration (FDA) granted approval for Mounjaro (tirzepatide) injection, a novel once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly and Company. This medication is indicated as a supplementary treatment, in conjunction with diet and exercise, for enhancing glycemic control in adults with type 2 diabetes.
Growing introduction of innovative drug products for treating prediabetes is predicted to boost the market growth during the forecast period. Prediabetes represents a transitional phase in glucose regulation, positioned between typical glucose tolerance and diagnosed diabetes. Individuals with prediabetes have elevated blood glucose levels beyond the normal range but do not meet the criteria for a diabetes diagnosis. Expressions such as impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are employed to describe this prediabetic state. Consequently, companies in the market are introducing new drug products specifically designed for treating prediabetes. For instance, in January 2024, Novo Nordisk has introduced Wegovy, a GLP-1 analogue, in the United Kingdom. This medication is available for prescription for individuals with prediabetes and for those seeking weight loss.
By age group, adults (18-49) was the highest revenue-grossing segment in the global prediabetes treatment market in 2023 owing to the growing prevalence of prediabetes and increased adoption of unhealthy lifestyles. Additionally, elderly (50+) is predicted to grow at the fastest CAGR during the forecast period owing to the rising geriatric population, expanding range of medication choices for prediabetes treatment, and increasing research & development efforts. For instance, in November 2023, VALBIOTIS SA reported the positive outcome of the mode-of-action clinical study for its product TOTUM•63 in the treatment of prediabetes.
By drug class, diguanides was the highest revenue-grossing segment in the global prediabetes treatment market in 2023 as their extensive use in managing prediabetes & type 2 diabetes, and increasing trend in the adoption of metformin for prediabetes treatment. Additionally, SGLT2 inhibitors is predicted to grow at the fastest CAGR during the forecast period owing to the growing use in the treatment for prediabetes, and increase in the number of clinical trial procedures. For instance, in April 2023, Aphaia Pharma has commenced the Phase 2 Trial for its potential drug, APH-012, intended for treating prediabetes.
By end-user, diagnostic center was the highest revenue-grossing segment in the global prediabetes treatment market in 2023 owing to the growing prevalence of prediabetes in the population, rise in the number of diagnostic tests, and increased efforts by market participants. For instance, in October 2023, The Ministry of Health and Prevention (MoHAP) has introduced a groundbreaking National Prediabetes and Diabetes Screening initiative. Utilizing screening centers throughout the UAE, the campaign aligns with the goal of achieving the National Indicator to decrease diabetes prevalence in the country. Additionally, hospitals is predicted to grow at the fastest CAGR during the forecast period owing to the upswing in the number of individuals affected by diabetes and growing need for innovative drug products designed for the treatment of prediabetes.
North America region is anticipated for the highest revenue share during the forecast period owing to the heightened awareness regarding the significance of early identification & intervention for prediabetes, rising prevalence of prediabetes, continuous progress in diagnostic technologies & therapeutic alternatives, and increase in research & development efforts. For instance, in July 2022, A patented extract of flavonoids derived from lemon, marketed under the name Eriomin by Ingredients By Nature (IMN), has been shown to be advantageous in the management of prediabetes, as reported in a study published in the Journal of Medical Food. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the widespread adoption of sedentary lifestyles, rising prevalence of prediabetes, surge in genetic predisposition, growing aging population, escalating prevalence obesity, and increasing number of approvals by regulatory bodies. For instance, in May 2022, The U.S. Food and Drug Administration (FDA) granted approval for Mounjaro (tirzepatide) injection, a novel once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist developed by Eli Lilly and Company. This medication is indicated as a supplementary treatment, in conjunction with diet and exercise, for enhancing glycemic control in adults with type 2 diabetes.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Type, Material, Product, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Prediabetes Treatment Market Report 2023 - 2034
Prediabetes Treatment Market Analysis & Forecast by Age Group 2023 - 2034 (Revenue USD Mn)
- Elderly (50+)
- Adults (18-49)
- Children (12-18 years)
Prediabetes Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Mn)
- Glucagon-like Peptide-1 Agonists (GLP-1)
- Thiazolidinediones
- DPP-4 Inhibitors
- SGLT2 Inhibitors
- Diguanide
- Others
Prediabetes Treatment Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Mn)
- Diagnostic Centers
- Hospitals
- Clinics & Laboratories
- Others
Prediabetes Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Prediabetes Treatment Market: Age Group Estimates & Trend Analysis
8. Prediabetes Treatment Market: Drug Class Estimates & Trend Analysis
9. Prediabetes Treatment Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Prediabetes Treatment Market
12. Europe Prediabetes Treatment Market
13. Asia Pacific Prediabetes Treatment Market
14. Latin America Prediabetes Treatment Market
15. MEA Prediabetes Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Sigma Aldrich
- Merck Millipore
- Acadia
- Amgen Roche
- Merck & Co
- Pfizer
- Actavis
- Novartis
- Actelion Pharmaceuticals Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 202.7 Million |
| Forecasted Market Value ( USD | $ 436.4 Million |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
